Profile data is unavailable for this security.
About the company
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.
- Revenue in CAD (TTM)--
- Net income in CAD--
- Incorporated1997
- Employees40.00
- LocationStageZero Life Sciences Ltd30-70 East Beaver Creek RoadRICHMOND HILL L4B 3B2CanadaCAN
- Phone+1 (905) 209-2030
- Fax+1 (905) 209-2030
- Websitehttps://www.stagezerolifesciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Appili Therapeutics Inc | 827.41k | -3.82m | 4.85m | 7.00 | -- | -- | -- | 5.86 | -0.0315 | -0.0315 | 0.0068 | -0.1021 | 0.3758 | -- | 0.6463 | 118,201.40 | -173.36 | -128.44 | -- | -251.87 | -- | -- | -461.35 | -2,103.81 | -- | -3.30 | -- | -- | 147.59 | -- | 59.09 | -- | 17.59 | -- |
| StageZero Life Sciences Ltd | -100.00bn | -100.00bn | 4.92m | 40.00 | -- | -- | -- | -- | -- | -- | -- | -0.1209 | -- | -- | -- | -- | -- | -135.76 | -- | -- | -- | -2.74 | -- | -246.92 | 0.0204 | -- | -- | -- | -25.12 | 55.93 | -52.53 | -- | -- | -- |
| Quest PharmaTech Inc | 0.00 | 13.58m | 5.07m | 0.00 | 0.3737 | 0.2205 | 0.3737 | -- | 0.0803 | 0.0803 | 0.00 | 0.136 | 0.00 | -- | -- | -- | 53.30 | 7.62 | 55.60 | 8.45 | -- | -- | -- | -- | -- | -- | 0.0417 | 0.00 | -- | -- | 95.35 | -- | -- | -- |
| Innovotech Inc | 1.23m | -364.50k | 5.86m | 16.00 | -- | 8.02 | -- | 4.77 | -0.0094 | -0.0094 | 0.0315 | 0.0187 | 1.10 | 5.81 | 5.84 | -- | -32.59 | 2.90 | -37.99 | 3.56 | 68.63 | 71.56 | -29.67 | 2.19 | 2.17 | -- | 0.1115 | -- | 5.05 | 7.42 | -15.43 | -- | 35.69 | -- |
| Marvel Biosciences Corp | 0.00 | -2.10m | 6.05m | -- | -- | -- | -- | -- | -0.0529 | -0.0529 | 0.00 | -0.0693 | 0.00 | -- | -- | -- | -268.48 | -- | -- | -- | -- | -- | -- | -- | -- | -14.33 | -- | -- | -- | -- | 10.29 | -- | -- | -- |
| Principal Technologies Inc | 618.64k | -1.90m | 6.08m | -- | -- | 10.02 | -- | 9.83 | -0.0766 | -0.0766 | 0.0246 | 0.0165 | 0.5664 | -- | 2.92 | -- | -170.72 | -- | -445.11 | -- | 21.57 | -- | -301.45 | -- | -- | -31.95 | 0.0959 | -- | 25.43 | -- | 23.53 | -- | -- | -- |
| XORTX Therapeutics Inc | 0.00 | -2.06m | 6.45m | 3.00 | -- | 1.71 | -- | -- | -0.6967 | -0.6967 | 0.00 | 1.30 | 0.00 | -- | -- | -- | -23.54 | -35.42 | -29.36 | -40.37 | -- | -- | -- | -- | -- | -- | 0.03 | -- | -- | -- | 72.04 | -- | 7.91 | -- |
| Rakovina Therapeutics Inc | 0.00 | -2.94m | 7.22m | -- | -- | 1.77 | -- | -- | -0.0419 | -0.0419 | 0.00 | 0.0452 | 0.00 | -- | -- | -- | -46.65 | -- | -51.51 | -- | -- | -- | -- | -- | -- | -13.01 | 0.2652 | -- | -- | -- | 6.39 | -- | -- | -- |
